PTH(1–34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life | Zendy

Andrea Palermo | Zendy; Assunta Santonati | Zendy; Gaia Tabacco | Zendy; Daniela Bosco | Zendy; Antonio Spada | Zendy; Claudio Pedone | Zendy; Bruno Raggiunti | Zendy; Tina Doris | Zendy; Daria Maggi | Zendy; Franco Grimaldi | Zendy; Silvia Manfrini | Zendy; Fabio Vescini | Zendy

Open Access

PTH(1–34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life

Author(s) -

Andrea Palermo,

Assunta Santonati,

Gaia Tabacco,

Daniela Bosco,

Antonio Spada,

Claudio Pedone,

Bruno Raggiunti,

Tina Doris,

Daria Maggi,

Franco Grimaldi,

Silvia Manfrini,

Fabio Vescini

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-01555

Subject(s) - medicine , hypoparathyroidism , calcitriol , parathyroid hormone , vitamin d and neurology , calcium , prospective cohort study , open label , quality of life (healthcare) , endocrinology , urology , gastroenterology , clinical trial , nursing

Daily parathyroid hormone (PTH) (1-34) administrations can reduce the required total daily dose of calcium and calcitriol and restore normocalcemia in refractory hypoparathyroidism. However, most PTH(1-34) trials have been conducted on small cohorts including subjects with hypoparathyroidism of various etiologies, and quality of life (QOL) was not investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research